Physician profile
Michelle Lee
NPI 1366824807
$6,069.79
in general payments reported to CMS, 2019-2025
22 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,159 · 2020: $658 · 2021: $143 · 2022: $816 · 2023: $1,034 · 2024: $922 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,195 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,195.43 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,000.06 | 2019-2025 | |
| Genzyme Corporation | $748.70 | 2022-2025 | |
| Janssen Biotech, INC. | $504.22 | 2020-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $478.20 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $413.71 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $306.52 | 2019-2025 | Xifaxan |
| Janssen Scientific Affairs, LLC | $266.72 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $216.76 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $201.96 | 2019-2021 | |
| Madrigal Pharmaceuticals | $173.64 | 2024-2025 | Resmetirom, Rezdiffra |
| Olympus America INC. | $143.84 | 2019-2023 | Olympus Endotherapy Inflation Device For Endoscopic Balloon Dilation |
| Si-Bone, INC. | $137.36 | 2025 | |
| Celltrion USA INC. | $122.31 | 2025 | Zymfentra |
| Allergan, INC. | $97.33 | 2019 | |
| Ardelyx, INC. | $48.82 | 2025 | Ibsrela |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $47.02 | 2020-2023 | Linzess |
| Qol Medical, LLC | $46.41 | 2022-2024 | Sucraid |
| Celgene Corporation | $36.49 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $28.96 | 2025 | Suflave |
| Fresenius Kabi USA, LLC | $18.02 | 2019 | |
| Merck Sharp & Dohme LLC | $17.22 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.